Dangerous Drugs Citation and Commencement 1 These Regulations may be cited as the Misuse of Drugs (Amendment) Regulations (Northern Ireland) 2009 and shall come into operation on 23rd December 2009. Interpretation 2 1 In these Regulations, “the 2002 Regulations” means the Misuse of Drugs Regulations (Northern Ireland) 2002 2 The Interpretation Act (Northern Ireland) 1954 shall apply to these Regulations as it applies to an Act of the Assembly. Amendments to the 2002 Regulations 3 The 2002 Regulations shall be amended as follows. 4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5 1 In Schedule 1 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 23, 26 and 27)— a in paragraph 1(a)— i after “Concentrate of poppy-straw”, insert— [2,3–Dihydro–5–methyl–3–(4–morpholinylmethyl)pyrrolo[1,2,3– de ]–1,4–benzoxazin–6–yl]–1–naphthalenylmethanone 3–Dimethylheptyl–11–hydroxyhexahydrocannabinol ; ii after “Fungus (of any kind) which contains psilocin or an ester of psilocin” , insert— [9–Hydroxy–6–methyl–3–[5–phenylpentan–2–yl] oxy–5, 6, 6a, 7, 8, 9, 10, 10a–octahydrophenanthridin–1–yl] acetate 9-(Hydroxymethyl)–6, 6–dimethyl–3–(2–methyloctan–2–yl)–6a, 7, 10, 10a–tetrahydrobenzo[ c ]chromen–1–ol ; b after paragraph 1(f), insert— g 1–benzylpiperazine or any compound (not being a compound for the time being specified in Schedule 4) structurally derived from 1–benzylpiperazine or 1–phenylpiperazine by modification in any of the following ways— i by substitution at the second nitrogen atom of the piperazine ring with alkyl, benzyl, haloalkyl or phenyl groups; ii by substitution in the aromatic ring to any extent with alkyl, alkoxy, alkylenedioxy, halide or haloalkyl groups; h any compound structurally derived from 3–(1–naphthoyl)indole or 1 H –indol–3–yl–(1–naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; i any compound structurally derived from 3–(1–naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent; j any compound structurally derived from 1–(1–naphthylmethyl)indene by substitution at the 3–position of the indene ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent; k any compound structurally derived from 3–phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent; l any compound structurally derived from 2–(3–hydroxycyclohexyl)phenol by substitution at the 5–position of the phenolic ring by alkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl or 2–(4–morpholinyl)ethyl, whether or not further substituted in the cyclohexyl ring to any extent. 2 In paragraph 1 of Schedule 2 (which specifies controlled drugs subject to the requirements of regulations 14, 15, 16, 18, 19, 20, 21, 23, 26 and 27)— a after “Myrophine”, insert “Nabilone”; b after “Norpipanone”, insert “Oripavine”. 3 In paragraph 1 of Part 1 of Schedule 4 (which specifies controlled drugs subject to the requirements of regulations 22, 23, 26 and 27), after “Chlordiazepoxide”, insert— 1–(3–chlorophenyl)piperazine 1–(3–chlorophenyl)–4–(3–chloropropyl)piperazine . 4 In Part 2 of Schedule 4 (controlled drugs excepted from the prohibition on possession when in the form of a medicinal product)— a in paragraph 1— i before “4–Androstene–3,17–dione” , insert— 5α–Androstane–3,17–diol Androst-4-ene-3,17-diol 1–Androstenediol 1–Androstenedione ; ii after “4–Androstene–3,17–dione”, insert “5–Androstenedione”; iii after “Boldenone”, insert “Boldione”; iv after “Clostebol”, insert— Danazol Desoxymethyltestosterone ; v after “Furazabol”, insert— Gestrinone 3–Hydroxy–5α–androstan–17–one ; vi after “Nandrolone”, insert “19–Norandrostenedione”; vii after “19–Nor–5–Androstene–3,17–diol” , insert “19–Norandrosterone”; viii after “Norethandrolone”, insert “19–Noretiocholanolone”; ix after “Propetandrol”, insert “Prostanozol”; x after “Testosterone”, insert “Tetrahydrogestrinone”; b in paragraph 4, after “Somatropin”, insert— Zeranol Zilpaterol . Sealed with the Official Seal of the Department of Health, Social Services and Public Safety on 25th November 2009 (L.S.) Norman Morrow A Senior Officer of the Department of Health, Social Services and Public Safety